Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Ibrutinib Resistance”

9 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 9 of 9 results

Testing effectiveness (Phase 2)Study completedNCT01779791
What this trial is testing

PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma

Who this might be right for
Lymphoma
Janssen Research & Development, LLC 110
Not applicableUnknownNCT02267590
What this trial is testing

Tissue Collection for Biomarkers Determining Resistance to Ibrutinib

Who this might be right for
Mantle Cell LymphomaChronic Lymphocytic Leukaemia
Royal Marsden NHS Foundation Trust 120
Testing effectiveness (Phase 2)Study completedNCT02581930
What this trial is testing

Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma

Who this might be right for
Metastatic MelanomaRecurrent Cutaneous MelanomaStage IV Cutaneous Melanoma AJCC v6 and v7
National Cancer Institute (NCI) 18
Early research (Phase 1)WithdrawnNCT04043845
What this trial is testing

ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies

Who this might be right for
Chronic Lymphocytic LeukemiaWaldenstrom MacroglobulinemiaMantle Cell Lymphoma+1 more
Dana-Farber Cancer Institute
Testing effectiveness (Phase 2)Ended earlyNCT04209621
What this trial is testing

Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Who this might be right for
Small Lymphocytic Leukemia (SLL)Chronic Lymphocytic Leukemia (CLL)
National Heart, Lung, and Blood Institute (NHLBI) 3
Testing effectiveness (Phase 2)Active Not RecruitingNCT03513562
What this trial is testing

Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations

Who this might be right for
Chronic Lymphocytic LeukemiaIbrutinib Resistance
Ohio State University Comprehensive Cancer Center 28
Early research (Phase 1)Ended earlyNCT04477291
What this trial is testing

CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic Syndromes
Aptose Biosciences Inc. 45
Not applicableStudy completedNCT03502876
What this trial is testing

Tolerance and Resistance to Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL

Who this might be right for
B Cell Chronic Lymphocytic Leukemia
French Innovative Leukemia Organisation 198
Testing effectiveness (Phase 2)WithdrawnNCT03943342
What this trial is testing

Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib Resistance

Who this might be right for
Chronic Lymphocytic LeukemiaLoss of Chromosome 17p
Kerry Rogers